Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical programs are in markets with billion dollar opportunities and include three allogeneic ('off-the-shelf') product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer.

Company profile
Ticker
LCTX
Exchange
Website
CEO
Brian Culley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
BIOTIME INC
SEC CIK
Corporate docs
Subsidiaries
Asterias Biotherapeutics, Inc. • Cell Cure Neurosciences Ltd • ES Cell International Pte. Ltd • OrthoCyte Corporation ...
IRS number
943127919
LCTX stock data
News

Recap: Lineage Cell Therapeutics Q2 Earnings
11 Aug 22
Lineage Cell Therapeutics Q2 EPS $(0.04), Inline, Sales $4.55M Beat $3.68M Estimate
11 Aug 22
Earnings Scheduled For August 11, 2022
11 Aug 22
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
8 Jul 22
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
14 Jun 22
Press releases
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
11 Aug 22
Thinking about buying stock in Sonim Technologies, Li Auto, Enovix, Concert Pharmaceuticals, or Lineage Cell Therapeutics?
14 Jun 22
Thinking about buying stock in AeroClean Technologies, Kaival Brands Innovations, National Vision, Lineage Cell Therapeutics, or New Oriental Education?
14 Jun 22
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
2 Jun 22
Analyst ratings and price targets
Investment data
Securities sold
Number of investors
Calendar
11 Aug 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.86M | 70.86M | 70.86M | 70.86M | 70.86M | 70.86M |
Cash burn (monthly) | 2.4M | (no burn) | 2.26M | 4.25M | 2.35M | (no burn) |
Cash used (since last report) | 3.49M | n/a | 3.28M | 6.16M | 3.42M | n/a |
Cash remaining | 67.37M | n/a | 67.58M | 64.69M | 67.44M | n/a |
Runway (months of cash) | 28.1 | n/a | 29.9 | 15.2 | 28.6 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 22 | Kingsley Alfred D | Stock Option Common Shares | Grant | Acquire A | No | No | 1.57 | 50,000 | 78.5K | 50,000 |
1 Jul 22 | Bailey Don M | Stock Option Common Shares | Grant | Acquire A | No | No | 1.57 | 50,000 | 78.5K | 50,000 |
1 Jul 22 | Russell Angus C. | Stock Option Common Shares | Grant | Acquire A | No | No | 1.57 | 50,000 | 78.5K | 50,000 |
1 Jul 22 | Anula Jayasuriya | Stock Option Common Shares | Grant | Acquire A | No | No | 1.57 | 50,000 | 78.5K | 50,000 |
Institutional ownership, Q1 2022
63.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 107 |
Opened positions | 10 |
Closed positions | 27 |
Increased positions | 21 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 162.71M |
Total shares | 107.74M |
Total puts | 67.5K |
Total calls | 177.9K |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Broadwood Partners | 34.94M | $48.91M |
Broadwood Capital | 34.94M | $53.8M |
BLK Blackrock | 9.81M | $15.11M |
Vanguard | 5.96M | $9.17M |
Defender Capital | 5.01M | $7.98M |
Geode Capital Management | 2.28M | $3.5M |
STT State Street | 2.11M | $3.24M |
Prescott General Partners | 1.85M | $2.85M |
JPM JPMorgan Chase & Co. | 1.85M | $2.85M |
Raffles Associates | 1.31M | $2.01M |
Financial report summary
?Competition
International Stem Cell • Astellas Pharma • IVERIC bio • VistaGen Therapeutics • Astellas Pharma • Apellis Pharmaceuticals • Biostage • RPEContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
cervical, edited, faster, inflation, mitigate, outpace, paragraph, sublessee, sunset, thoracic, weakening
Removed:
abatement, allegedly, capacity, defer, epithelial, expired, footnote, Historically, implementation, industrial, leasehold, minimal, NOL, permitted, prepaid, proceeding, qualified, ranging, rendered, trade, varying
Financial reports
Current reports
8-K
LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
11 Aug 22
8-K
Departure of Directors or Certain Officers
7 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 22
8-K
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
12 May 22
8-K
Regulation FD Disclosure
11 May 22
8-K
LINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
10 Mar 22
8-K
Other Events
14 Feb 22
8-K
Other Events
21 Dec 21
8-K
Entry into a Material Definitive Agreement
20 Dec 21
8-K
Regulation FD Disclosure
13 Dec 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
21 Dec 21
S-8
Registration of securities for employees
28 Sep 21
S-8
Registration of securities for employees
11 Mar 21
424B5
Prospectus supplement for primary offering
5 Mar 21
S-3
Shelf registration
30 Apr 20
S-8
Registration of securities for employees
8 Aug 19
425
Business combination disclosure
28 Feb 19
424B3
Prospectus supplement
4 Feb 19
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEFA14A
Additional proxy soliciting materials
2 Sep 21
DEFA14A
Additional proxy soliciting materials
3 Aug 21
DEFA14A
Additional proxy soliciting materials
9 Aug 20
DEFA14A
Additional proxy soliciting materials
14 Jun 19
DEF 14A
Definitive proxy
28 Mar 18
Other
EFFECT
Notice of effectiveness
22 Mar 21
EFFECT
Notice of effectiveness
22 Mar 21
CORRESP
Correspondence with SEC
16 Mar 21
CORRESP
Correspondence with SEC
16 Mar 21
UPLOAD
Letter from SEC
15 Mar 21
UPLOAD
Letter from SEC
15 Mar 21
EFFECT
Notice of effectiveness
11 May 20
CORRESP
Correspondence with SEC
5 May 20
UPLOAD
Letter from SEC
5 May 20
CT ORDER
Confidential treatment order
13 Dec 17
Ownership
3
Lineage Cell Therapeutics / Alexandra Hernandez ownership change
8 Jul 22
SC 13G
Lineage Cell Therapeutics / BlackRock ownership change
8 Jul 22
4
Lineage Cell Therapeutics / Angus C. Russell ownership change
6 Jul 22
4
Lineage Cell Therapeutics / DEBORAH J ANDREWS ownership change
6 Jul 22
4
Lineage Cell Therapeutics / Anula Jayasuriya ownership change
6 Jul 22
4
Lineage Cell Therapeutics / Michael H. Mulroy ownership change
6 Jul 22
4
Lineage Cell Therapeutics / ALFRED D KINGSLEY ownership change
6 Jul 22
4
Lineage Cell Therapeutics / DON M BAILEY ownership change
6 Jul 22
4
Lineage Cell Therapeutics / NEAL C BRADSHER ownership change
6 Jul 22
4
Lineage Cell Therapeutics / Dipti Amin ownership change
6 Jul 22
Patents
Utility
Methods for Measuring Therapeutic Effects of Retinal Disease Therapies
2 Jun 22
Described herein are compositions and methods for treating retinal diseases or disorders using RPE cells.
Utility
Rpe Cell Populations and Methods of Generating Same
2 Jun 22
A population of human polygonal RPE cells is disclosed.
Utility
Rpe Cell Populations and Methods of Generating Same
2 Jun 22
A population of human polygonal RPE cells is disclosed.
Utility
Retinal Pigment Epithelium Cell Compositions
31 Mar 22
Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries.
Utility
Preparation of Retinal Pigment Epithelium Cells
16 Dec 21
A method of generating retinal pigment epithelium cells is disclosed.
Transcripts
2022 Q2
Earnings call transcript
12 Aug 22
2022 Q1
Earnings call transcript
13 May 22
2021 Q4
Earnings call transcript
11 Mar 22
2021 Q3
Earnings call transcript
11 Nov 21
2021 Q2
Earnings call transcript
13 Aug 21
2021 Q1
Earnings call transcript
14 May 21
2020 Q4
Earnings call transcript
12 Mar 21
2020 Q3
Earnings call transcript
4 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
7 May 20
Reddit threads
Daily Discussion Thread - August 11th, 2022
11 Aug 22
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Weekend Discussion Thread
22 Jul 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Daily Plays May 03, 2022
3 May 22
Daily Plays April 19, 2022
19 Apr 22
Daily Discussion Thread - March 10th, 2022
10 Mar 22
Daily Discussion Thread - March 9th, 2022
9 Mar 22
Daily Discussion Thread - March 8th, 2022
8 Mar 22